Literature DB >> 31482482

Safety and Utility of Liver Biopsy During Bariatric Surgery in the New Zealand Setting.

Hannah Collins1, Grant Beban2, John Windsor3, Rishi Ram2, David Orr2, Nicholas Evennett2, Benjamin Loveday4.   

Abstract

BACKGROUND: Asymptomatic liver disease is common in bariatric patients and can be diagnosed with intraoperative biopsy. This study aimed to establish the risk-benefit profile of routine liver biopsy, prevalence of clinically significant liver disease, relationship between liver pathology and body mass index, and compare outcomes between ethnic groups.
METHODS: This retrospective cohort study included all patients who had index bariatric surgery at Auckland City Hospital between 2009 and 2016. Diagnosis of liver disease was based on intraoperative biopsy histology. Outcomes included safety (biopsy-related complication) and utility (liver pathology meeting criteria for referral). Liver pathology and referral rates were compared between ethnic groups.
RESULTS: Of 335 bariatric surgery patients, 234 (70%) underwent intraoperative liver biopsy. There were no biopsy-related complications. Histological findings were as follows: normal 25/234 (11%), non-alcoholic fatty liver disease (NAFLD) 207/234 (88%), and other pathological findings in 35/234 (15%). Histological finding meeting referral criteria was present in 22/234 (9%). Of these, 12/22 (55%) were referred. Number needed to biopsy to identify histology meeting referral criteria: n = 11. Māori had a similar NAFLD rate to non-Māori [51/56 versus 156/178, p = 0.48]. Pasifika patients had a higher rate than non-Pasifika [39/40 versus 168/194, p = 0.049]. Māori and Pasifika patients had similar referral rates to non-Māori and non-Pasifika [2/3 versus 5/9, p = 0.73; 2/2 versus 5/10, p = 0.19].
CONCLUSIONS: Intraoperative liver biopsy during bariatric surgery is safe and identified liver disease in 89%, with 9% meeting referral criteria. Pasifika patients have a higher rate of NAFLD than non-Pasifika.

Entities:  

Keywords:  Bariatric surgery; Hepatology; Liver biopsy; Non-alcoholic fatty liver disease

Mesh:

Year:  2020        PMID: 31482482     DOI: 10.1007/s11695-019-04161-3

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  29 in total

1.  Hepatic histology in obese patients undergoing bariatric surgery.

Authors:  Mariana Machado; Pedro Marques-Vidal; Helena Cortez-Pinto
Journal:  J Hepatol       Date:  2006-07-25       Impact factor: 25.083

2.  Reversibility of liver fibrosis.

Authors:  David A Brenner
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-11

Review 3.  Monitoring of Liver Function Tests after Roux-en-Y Gastric Bypass: An Examination of Evidence Base.

Authors:  Kamal K Mahawar; Chetan Parmar; Yitka Graham; Nimantha De Alwis; William R J Carr; Neil Jennings; Peter K Small
Journal:  Obes Surg       Date:  2016-10       Impact factor: 4.129

4.  Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland.

Authors:  F Froehlich; O Lamy; M Fried; J J Gonvers
Journal:  Dig Dis Sci       Date:  1993-08       Impact factor: 3.199

5.  Hepatic pathology among patients without known liver disease undergoing bariatric surgery: observations and a perspective from the longitudinal assessment of bariatric surgery (LABS) study.

Authors:  David E Kleiner; Paul D Berk; Jesse Y Hsu; Anita P Courcoulas; David Flum; Saurabh Khandelwal; John Pender; Alfons Pomp; James Roerig; Laura L Machado; Bruce M Wolfe; Steven H Belle
Journal:  Semin Liver Dis       Date:  2014-04-29       Impact factor: 6.115

6.  Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis.

Authors:  Yung Lee; Aristithes G Doumouras; James Yu; Karanbir Brar; Laura Banfield; Scott Gmora; Mehran Anvari; Dennis Hong
Journal:  Clin Gastroenterol Hepatol       Date:  2018-10-13       Impact factor: 11.382

Review 7.  Benefit-risk of intraoperative liver biopsy during bariatric surgery: review and perspectives.

Authors:  Sandrine Barbois; Catherine Arvieux; Vincent Leroy; Fabian Reche; Nathalie Stürm; Anne-Laure Borel
Journal:  Surg Obes Relat Dis       Date:  2017-08-14       Impact factor: 4.734

8.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

9.  The incapacity of the surgeon to identify NASH in bariatric surgery makes biopsy mandatory.

Authors:  Antônio Roberto Franchi Teixeira; Marta Bellodi-Privato; José Barreto Carvalheira; Victor Fernando Pilla; José Carlos Pareja; Luiz Augusto Carneiro D'Albuquerque
Journal:  Obes Surg       Date:  2009-12       Impact factor: 4.129

10.  Outcome of patients hospitalized for complications after outpatient liver biopsy.

Authors:  C H Janes; K D Lindor
Journal:  Ann Intern Med       Date:  1993-01-15       Impact factor: 25.391

View more
  1 in total

1.  Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology.

Authors:  James Neuberger; Jai Patel; Helen Caldwell; Susan Davies; Vanessa Hebditch; Coral Hollywood; Stefan Hubscher; Salil Karkhanis; Will Lester; Nicholas Roslund; Rebecca West; Judith I Wyatt; Mathis Heydtmann
Journal:  Gut       Date:  2020-05-28       Impact factor: 23.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.